Proton pump inhibitors reduce phlebotomy burden in patients with HFE-related hemochromatosis: a systematic review and meta-analysis

Dirweesh, Ahmed; Anugwom, Chimaobi M.; Li, Yiting; Vaughn, Byron P.; Lake, John R.

doi:10.1097/meg.0000000000001857

Cited by 4 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The aforementioned results were confirmed by meta-analysis which involved 68 patients with HH (34 in the PPI group and 34 in the placebo or non-PPI group). The minimum duration of PPI treatment was the same (1 year) [104]. However, the routine use of PPIs in the treatment of HH is not recommended.…”

Section: Proton Pump Inhibitors -An Adjunct Therapy For Hereditary He...mentioning

confidence: 99%

Hereditary Hemochromatosis – How Not to Overlook and Properly Manage “Iron People”- a Critical Overview

Szczerbinska,

Kasztelan-Szczerbinska,

Rycyk-Bojarzynska

et al. 2024

Preprint

View full text Add to dashboard Cite

Hereditary hemochromatosis (HH) is the main genetic cause of iron overload and is regarded as metal-related human toxicosis. HH may result from HFE and non-HFE gene mutations causing hepcidin deficiency or hepcidin resistance. The disorder has a high biochemical penetrance, but a low clinical prevalence. Unfortunately, the majority of patients with HH remain undiagnosed at their disease-curable stage. The main aim of HH therapy is to prevent iron overload in the early-phase disease and elimination of excess iron from the body by phlebotomy in its late stage. Raising global awareness of HH among health professionals, their training to pay attention to early HH signs and symptoms, and strict patient monitoring are critical management strategies for preventing treatment delays, upgrading its efficacy, and improving patient prognosis.

show abstract

Section: Proton Pump Inhibitors -An Adjunct Therapy For Hereditary He...mentioning

confidence: 99%

Hereditary Hemochromatosis – How Not to Overlook and Properly Manage “Iron People”- a Critical Overview

Szczerbinska,

Kasztelan-Szczerbinska,

Rycyk-Bojarzynska

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…The aforementioned results were confirmed by a meta-analysis that involved 68 HC patients (34 in the PPI group and 34 in the placebo or non-PPI group). The minimal time of PPI treatment was the same (1 year) for all the patients [101]. However, regular PPI treatment is not currently recommended in patients with HC.…”

Section: Proton Pump Inhibitors-an Adjunct Therapy For Hemochromatosis?mentioning

confidence: 99%

Hemochromatosis—How Not to Overlook and Properly Manage “Iron People”—A Review

Szczerbinska,

Kasztelan-Szczerbinska,

Rycyk-Bojarzynska

et al. 2024

JCM

View full text Add to dashboard Cite

Hemochromatosis (HC) is the main genetic disorder of iron overload and is regarded as metal-related human toxicosis. HC may result from HFE and rare non-HFE gene mutations, causing hepcidin deficiency or, sporadically, hepcidin resistance. This review focuses on HFE-related HC. The illness presents a strong biochemical penetrance, but its prevalence is low. Unfortunately, the majority of patients with HC remain undiagnosed at their disease-curable stage. The main aim of HC management is to prevent iron overload in its early phase and remove excess iron from the body by phlebotomy in its late stage. Raising global awareness of HC among health staff, teaching them how not to overlook early HC manifestations, and paying attention to careful patient monitoring remain critical management strategies for preventing treatment delays, upgrading its efficacy, and improving patient prognosis.

show abstract

“…Vitamin E and omega-3 fatty acids combat the oxidative stress of iron overload [11 ▪ ]. Gastric acid is a known promoter of iron absorption therefore the use of antacids, proton pump inhibitors, or H2 blockers decrease phlebotomy burden [16]. Avoid multivitamins with high vitamin C content (Table 1).…”

Section: Common Patient Questionsmentioning

confidence: 99%

Proposed dietary recommendations for iron overload: a guide for physician practice

Saleh¹,

Seaman²,

Palmer

2023

Current Opinion in Gastroenterology

View full text Add to dashboard Cite

Purpose of reviewIron overload disorders such as hemochromatosis involve unregulated absorption of dietary iron, leading to excessive iron accumulation in multiple organs. Phlebotomy is the standard of care for removal of excess iron, but dietary modification is not standardized in practice. The purpose of this article is to help standardize hemochromatosis diet counseling based on commonly asked patient questions. Recent findingsThe clinical benefit regarding dietary modification in iron overload patients is limited due to lack of large clinical trials, but preliminary results are promising. Recent studies suggest diet modification could reduce iron burden in hemochromatosis patients resulting in less annual phlebotomy as supported through small patient studies, concepts of physiology, and animal studies. SummaryThis article is a guide for physicians to counsel hemochromatosis patients based on commonly asked questions such as foods to avoid, foods to consume, use of alcohol, and use of supplements. The goal of this guide is to help standardize hemochromatosis diet counseling to reduce phlebotomy amount in patients. Standardization of diet counseling could help facilitate future patient studies to analyze the clinical significance.

show abstract

Proton pump inhibitors reduce phlebotomy burden in patients with HFE-related hemochromatosis: a systematic review and meta-analysis

Cited by 4 publications

References 25 publications

Hereditary Hemochromatosis – How Not to Overlook and Properly Manage “Iron People”- a Critical Overview

Hereditary Hemochromatosis – How Not to Overlook and Properly Manage “Iron People”- a Critical Overview

Hemochromatosis—How Not to Overlook and Properly Manage “Iron People”—A Review

Proposed dietary recommendations for iron overload: a guide for physician practice

Contact Info

Product

Resources

About